Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus STREPTOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus STREPTOMYCIN SULFATE.
BRISTAGEN vs STREPTOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by causing misreading of mRNA and preventing initiation complex formation.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Intramuscular: 15 mg/kg/day (max 1 g/day) divided every 12 hours; intraperitoneal: 1 g/dialysis cycle; intrathecal: 1 mg/kg/day.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Terminal elimination half-life is 2-3 hours in patients with normal renal function. In anuria or severe renal impairment, half-life may extend to 50-100 hours. Neonates have a prolonged half-life of 5-10 hours due to immature renal function.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Primarily renal excretion via glomerular filtration; 80-98% of the dose is excreted unchanged in urine within 24 hours. Minor biliary excretion (less than 1%). Fecal excretion is negligible.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic